On May 15, 2024 Pacylex Pharmaceuticals Inc. (Pacylex) is a clinical-stage pharmaceutical company developing N-myristoyltransferase (NMT) inhibitors as targeted therapies for the treatment of hematologic cancers and solid tumors, reported that it will be attending the Biotechnology Innovation Organization (BIO) International Convention taking place June 3-6, 2024, at the San Diego Convention Center, in San Diego, California, USA (Press release, Pacylex Pharmaceuticals, MAY 15, 2024, View Source [SID1234645049]). The BIO Convention is the premier life sciences networking conference in the world, bringing together leaders, innovators and investors from the pharmaceutical, biotech and medical device industries.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Pacylex’s Chief Executive Officer, Dr. Michael Weickert, will be attending the conference and participating in the BIO One-on-One Partnering system. He will be available to review Pacylex’s recent clinical progress with zelenirstat currently being dosed in patients in two Phase 2a studies, in refractory and relapsed B-cell non-Hodgkin’s lymphoma and in advanced refractory colorectal cancer patients, at 4 clinical sites in Canada. He will also share new data describing how zelenirstat works in different cancers by inhibiting the myristoylation required for assembly, translocation, and/or function of validated targets like B-cell receptor, EGFR, and VEGFR. Zelenirstat also blocks Complex I formation in mitochondria of cancer cells which shuts down oxidative phosphorylation, especially critical for metastasis and cancer stem cells.
"We are learning from laboratory and clinical studies that inhibiting myristoylation appears to be an efficient way to turn off many cancer-critical processes with one switch", said Dr. Michael Weickert, CEO of Pacylex. "That may explain why Phase 1 zelenirstat patients with heavily pretreated and refractory ovarian, appendiceal, and colorectal cancer had 6 to 15 months of stable disease when treated with our recommended phase 2 dose. "
Registered attendees can discuss investment and licensing opportunities with Dr. Weickert by scheduling a meeting using the BIO One-on-One Partnering system. If there are no compatible time slots available, please contact Dr. Weickert directly to schedule a meeting.